Table 1 |.
Clinical trials of cell therapy for heart disease
| Trial name | Indication | Design; sponsor; phase | Number of patients projected | Delivery method |
|---|---|---|---|---|
| Bone marrow mononuclear cells | ||||
| REPEAT (NCT01693042) | Chronic post-infarction heart failure | Autologous cells, single versus dual infusion; academic; phase II–III | 676 | Intracoronary |
| CardiAMP Heart Failure Trial (NCT02438306) | Chronic post-infarction heart failure | Autologous cells, randomized with sham control; BioCardia; phase III | 250 | Transendocardial intramyocardial delivery |
| Andalucia DCM Trial (NCT02033278) | Dilated cardiomyopathy | Autologous cells, DBPCT; academic; phase II-III | 51 | Intracoronary |
| BAMI (NCT01569178) | Acute myocardial infarction | Autologous cells, randomized to cell infusion or standard care; academic; phase III | 350 | Intracoronary |
| Mesenchymal cells | ||||
| DREAM HF-1 (NCT02032004) | Chronic heart failure with reduced ejection fraction | Allogeneic MPCs, randomized with sham control; Mesoblast; phase III | 600 | Transendocardial intramyocardial delivery |
| Cardiosphere-derived cells | ||||
| HOPE-2 (NCT03406780) | Cardiomyopathy and skeletal myopathy of Duchenne muscular dystrophy | Allogeneic, multiple repetitive doses, DBPCT; Capricor; phase III | 80 | Intravenous |
| Combinations | ||||
| CONCERT-HF (NCT02501811) | Ischaemic cardiomyopathy | Autologous bone marrow MSCs and/or autologous c-kit-selected heart cells, DBPCT; academic; phase II | 144 | Transendocardial intramyocardial delivery |
Actively recruiting multicentre trials were taken from https://clinicaltrials.gov (accessed 22 February 2018). Each trial is listed with its National Clinical Trial identifier. DBPCT, double-blind placebo- controlled trial; MPC, mesenchymal precursor cell; MSC, mesenchymal stem cell.